市場調査レポート

商品コード

鎌状赤血球症治療の世界市場規模、シェア、産業動向分析レポート：治療別、エンドユース別、地域別展望と予測、2023年～2030年

Global Sickle Cell Disease Treatment Market Size, Share & Industry Trends Analysis Report By Treatment, By End-Use, By Regional Outlook and Forecast, 2023 - 2030

出版日: 2023年08月31日 | 発行: KBV Research

| ページ情報: 英文 203 Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 3,600 564,336円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 4,320 677,203円

レポートPDFを同一企業内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprisewide License)

USD 6,048 948,084円

レポートPDFを同一企業のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

鎌状赤血球症治療の市場規模は2030年までに73億米ドルに達すると予測され、予測期間中のCAGRは27.9%の市場成長率で上昇する見込みです。

KBV Cardinalのマトリックスに掲載された分析によると、ファイザーが同市場におけるトップランナーです。Novo Nordisk A/S社、Novartis AG社、Bristol Myers Squibb Company社などの企業は、市場における主要なイノベーターです。2019年10月、Novo Nordisk A/Sは、遺伝性疾患のためのin vivoゲノム編集治療法を開発するためにbluebird bio, Incとパートナーシップを締結しました。この提携により、ノボノルディスクは疾患修飾薬の開発により有利な立場に立つことになります。

COVID-19影響分析

ヘルスケア業界のワークフローは、世界中でCOVID-19の大流行によって妨げられました。ヘルスケアのいくつかのサブドメインを含むいくつかの産業は、病気の流行により一時的な閉鎖を余儀なくされました。市場拡大を制限するさらなる要因は、COVID-19の際に鎌状赤血球症治療薬のサプライチェーンが混乱したことです。さらに、病院の閉鎖は入院に悪影響を及ぼし、市場に影響を与えました。パンデミックの後期には、集団予防接種の増加、厳格なCOVID-19ガイドラインの実施、渡航制限の解除により、輸血および骨髄移植産業の成長は正常に戻っています。したがって、パンデミックは市場に大きなマイナスの影響を与えました。

市場成長要因

新しい治療法の開発

以前は、輸血と骨髄移植がSCDの唯一の治療法でした。SCDの有病率と認知度が高まるにつれ、代替となる効果的な治療法の需要が高まっています。主要企業は、市場の需要に応えるため、この疾患を治療する新製品の導入に重点を置くようになっています。エンダリは、数十年ぶりに承認されたブランド薬であり、それ以前は、この疾患の治療法を考案する上で技術革新に重点を置くことは限られていました。適切なドナーを持たない鎌状赤血球症患者は、自身の造血幹細胞を変化させる遺伝子治療によって治癒する可能性があります。このような市場開拓は、鎌状赤血球症に対する利用可能な治療法の数を増やし、多くの患者をカバーする可能性があるため、市場の成長を助長します。

臨床試験と製薬研究の近代化

製薬研究業界のリーダーたちは現在、研究開発プロセスの効率的な実施方法を模索しており、機械学習はその有望なソリューションと思われます。世界のトップ製薬会社は、新しい治療法を発見するヒット・アンド・ミスのプロセスを改善するために機械学習を利用しています。さらに、多くの大手製薬会社は、創薬プロセスをスピードアップするためのビッグデータの可能性を調査しています。これは、全体として、より小規模で、より迅速で、より安価な臨床試験につながると思われます。より安全性を高めるために、MLは遠隔モニタリングやリアルタイムのデータアクセスにも利用できます。そのため、より迅速で効果的な医薬品開発を可能にするMLを活用した製薬分野の臨床試験や研究開発の新興国市場の開拓は、市場の成長を促進すると思われます。

市場抑制要因

SCDの治療選択肢が少ない

鎌状赤血球症の治療に用いられる薬物療法は、ヒドロキシ尿素と少数のブランド薬です。多くのヘルスケア専門家がヒドロキシ尿素を第一選択薬として推奨しています。しかし、世界中の国や地域で治療の選択肢がないことが、大きな制約要因となっています。WHOの小児用必須医薬品モデルリストに含まれているにもかかわらず、ヒドロキシ尿素はこの地域ではまだ入手できないです。さらに、アフリカではこの物質は高価すぎると考えられています。さらに、新興経済諸国では国民の間でこの病気に対する認識が低いことも、予測期間中の市場開拓の妨げになる可能性があります。

治療法の展望

治療法によって、市場は輸血、薬物療法、骨髄移植に分類されます。骨髄移植セグメントは、2022年の市場でかなりの収益シェアを占めています。このセグメントは、新しいブランド医薬品の出現と、これらの医薬品を早期に上市するための政府のインセンティブが高まっているため、急速な拡大を経験しています。政府は鎌状赤血球症の研究を支援するため、希少疾病用医薬品、ファスト・トラック、優先審査などの資金援助や指定を行っています。

最終用途別の展望

最終用途に基づき、市場は病院、専門クリニック、その他に分類されます。2022年には、病院セグメントが市場で最大の売上シェアを占める。病気の診断と治療の主な中心は病院です。輸血や骨髄移植のほとんどは病院で行われます。加えて、優れたヘルスケアサービス、大規模な患者プール、充実した医療インフラが、このセグメントの市場シェアが大きい主な理由の1つです。

地域別展望

地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。2022年には、北米地域が最も高い収益シェアを獲得して市場をリードしました。同地域の拡大は、SCD治療薬の増加や有望なパイプライン候補に起因しています。米国の強力な政府支援は市場成長をさらに促進すると思われます。同地域の市場は、鎌状赤血球症の罹患率の増加、臨床試験件数の増加、製品上市件数の増加により、平均よりも急速に成長すると予測されます。

KBV Cardinal Matrix
最近の業界全体の戦略的展開
- パートナーシップ、コラボレーション、および契約
- 製品の発売と製品の拡大
- 買収と合併
- 試験と承認
主要成功戦略
- 主な戦略
- 主要な戦略的動き
ポーターファイブフォース分析

第5章世界の鎌状赤血球症治療市場：治療別

世界の輸血市場：地域別
世界の薬物療法市場：地域別
世界の骨髄移植市場：地域別

第6章世界の鎌状赤血球症治療市場：最終用途別

世界の病院市場：地域別
世界の専門クリニック市場：地域別
世界のその他の市場：地域別

第7章世界の鎌状赤血球症治療市場：地域別

北米
- 北米の市場：国別
  - 米国
  - カナダ
  - メキシコ
  - その他北米地域
欧州
- 欧州の市場：国別
  - ドイツ
  - 英国
  - フランス
  - ロシア
  - スペイン
  - イタリア
  - その他欧州地域
アジア太平洋
- アジア太平洋の市場：国別
  - 中国
  - 日本
  - インド
  - 韓国
  - シンガポール
  - マレーシア
  - その他アジア太平洋地域
ラテンアメリカ・中東・アフリカ
- ラテンアメリカ・中東・アフリカの市場：国別
  - ブラジル
  - アルゼンチン
  - アラブ首長国連邦
  - サウジアラビア
  - 南アフリカ
  - ナイジェリア
  - その他ラテンアメリカ・中東・アフリカ地域

第8章企業プロファイル

bluebird bio, Inc
CRISPR Therapeutics AG
Agios Pharmaceuticals, Inc（Les Laboratoires Servier SAS）
Medunik USA（Duchesnay Inc）
CSL Limited
Novo Nordisk A/S
Novartis AG
Pfizer, Inc
Bristol Myers Squibb Company
Emmaus Life Sciences, Inc

第9章鎌状赤血球症治療市場の勝利の必須条件

図表

LIST OF TABLES

TABLE 1 Global Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 2 Global Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements- Sickle Cell Disease Treatment Market
TABLE 4 Product Launches And Product Expansions- Sickle Cell Disease Treatment Market
TABLE 5 Acquisition and Mergers- Sickle Cell Disease Treatment Market
TABLE 6 Trials and Approvals- SICKLE Cell Disease Treatment Market
TABLE 7 Global Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 8 Global Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 9 Global Blood Transfusion Market by Region, 2019 - 2022, USD Million
TABLE 10 Global Blood Transfusion Market by Region, 2023 - 2030, USD Million
TABLE 11 Global Pharmacotherapy Market by Region, 2019 - 2022, USD Million
TABLE 12 Global Pharmacotherapy Market by Region, 2023 - 2030, USD Million
TABLE 13 Global Bone Marrow Transplant Market by Region, 2019 - 2022, USD Million
TABLE 14 Global Bone Marrow Transplant Market by Region, 2023 - 2030, USD Million
TABLE 15 Global Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 16 Global Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 17 Global Hospitals Market by Region, 2019 - 2022, USD Million
TABLE 18 Global Hospitals Market by Region, 2023 - 2030, USD Million
TABLE 19 Global Specialty Clinics Market by Region, 2019 - 2022, USD Million
TABLE 20 Global Specialty Clinics Market by Region, 2023 - 2030, USD Million
TABLE 21 Global Others Market by Region, 2019 - 2022, USD Million
TABLE 22 Global Others Market by Region, 2023 - 2030, USD Million
TABLE 23 Global Sickle Cell Disease Treatment Market by Region, 2019 - 2022, USD Million
TABLE 24 Global Sickle Cell Disease Treatment Market by Region, 2023 - 2030, USD Million
TABLE 25 North America Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 26 North America Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 27 North America Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 28 North America Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 29 North America Blood Transfusion Market by Country, 2019 - 2022, USD Million
TABLE 30 North America Blood Transfusion Market by Country, 2023 - 2030, USD Million
TABLE 31 North America Pharmacotherapy Market by Country, 2019 - 2022, USD Million
TABLE 32 North America Pharmacotherapy Market by Country, 2023 - 2030, USD Million
TABLE 33 North America Bone Marrow Transplant Market by Country, 2019 - 2022, USD Million
TABLE 34 North America Bone Marrow Transplant Market by Country, 2023 - 2030, USD Million
TABLE 35 North America Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 36 North America Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 37 North America Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 38 North America Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 39 North America Specialty Clinics Market by Country, 2019 - 2022, USD Million
TABLE 40 North America Specialty Clinics Market by Country, 2023 - 2030, USD Million
TABLE 41 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 42 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 43 North America Sickle Cell Disease Treatment Market by Country, 2019 - 2022, USD Million
TABLE 44 North America Sickle Cell Disease Treatment Market by Country, 2023 - 2030, USD Million
TABLE 45 US Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 46 US Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 47 US Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 48 US Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 49 US Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 50 US Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 51 Canada Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 52 Canada Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 53 Canada Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 54 Canada Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 55 Canada Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 56 Canada Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 57 Mexico Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 58 Mexico Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 59 Mexico Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 60 Mexico Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 61 Mexico Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 62 Mexico Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 63 Rest of North America Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 64 Rest of North America Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 65 Rest of North America Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 66 Rest of North America Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 67 Rest of North America Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 68 Rest of North America Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 69 Europe Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 70 Europe Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 71 Europe Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 72 Europe Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 73 Europe Blood Transfusion Market by Country, 2019 - 2022, USD Million
TABLE 74 Europe Blood Transfusion Market by Country, 2023 - 2030, USD Million
TABLE 75 Europe Pharmacotherapy Market by Country, 2019 - 2022, USD Million
TABLE 76 Europe Pharmacotherapy Market by Country, 2023 - 2030, USD Million
TABLE 77 Europe Bone Marrow Transplant Market by Country, 2019 - 2022, USD Million
TABLE 78 Europe Bone Marrow Transplant Market by Country, 2023 - 2030, USD Million
TABLE 79 Europe Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 80 Europe Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 81 Europe Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 82 Europe Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 83 Europe Specialty Clinics Market by Country, 2019 - 2022, USD Million
TABLE 84 Europe Specialty Clinics Market by Country, 2023 - 2030, USD Million
TABLE 85 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 86 Europe Others Market by Country, 2023 - 2030, USD Million
TABLE 87 Europe Sickle Cell Disease Treatment Market by Country, 2019 - 2022, USD Million
TABLE 88 Europe Sickle Cell Disease Treatment Market by Country, 2023 - 2030, USD Million
TABLE 89 Germany Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 90 Germany Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 91 Germany Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 92 Germany Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 93 Germany Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 94 Germany Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 95 UK Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 96 UK Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 97 UK Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 98 UK Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 99 UK Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 100 UK Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 101 France Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 102 France Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 103 France Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 104 France Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 105 France Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 106 France Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 107 Russia Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 108 Russia Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 109 Russia Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 110 Russia Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 111 Russia Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 112 Russia Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 113 Spain Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 114 Spain Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 115 Spain Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 116 Spain Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 117 Spain Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 118 Spain Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 119 Italy Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 120 Italy Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 121 Italy Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 122 Italy Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 123 Italy Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 124 Italy Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 125 Rest of Europe Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 126 Rest of Europe Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 127 Rest of Europe Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 128 Rest of Europe Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 129 Rest of Europe Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 130 Rest of Europe Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 131 Asia Pacific Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 132 Asia Pacific Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 133 Asia Pacific Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 134 Asia Pacific Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 135 Asia Pacific Blood Transfusion Market by Country, 2019 - 2022, USD Million
TABLE 136 Asia Pacific Blood Transfusion Market by Country, 2023 - 2030, USD Million
TABLE 137 Asia Pacific Pharmacotherapy Market by Country, 2019 - 2022, USD Million
TABLE 138 Asia Pacific Pharmacotherapy Market by Country, 2023 - 2030, USD Million
TABLE 139 Asia Pacific Bone Marrow Transplant Market by Country, 2019 - 2022, USD Million
TABLE 140 Asia Pacific Bone Marrow Transplant Market by Country, 2023 - 2030, USD Million
TABLE 141 Asia Pacific Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 142 Asia Pacific Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 143 Asia Pacific Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 144 Asia Pacific Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 145 Asia Pacific Specialty Clinics Market by Country, 2019 - 2022, USD Million
TABLE 146 Asia Pacific Specialty Clinics Market by Country, 2023 - 2030, USD Million
TABLE 147 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 148 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
TABLE 149 Asia Pacific Sickle Cell Disease Treatment Market by Country, 2019 - 2022, USD Million
TABLE 150 Asia Pacific Sickle Cell Disease Treatment Market by Country, 2023 - 2030, USD Million
TABLE 151 China Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 152 China Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 153 China Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 154 China Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 155 China Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 156 China Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 157 Japan Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 158 Japan Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 159 Japan Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 160 Japan Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 161 Japan Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 162 Japan Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 163 India Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 164 India Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 165 India Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 166 India Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 167 India Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 168 India Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 169 South Korea Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 170 South Korea Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 171 South Korea Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 172 South Korea Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 173 South Korea Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 174 South Korea Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 175 Singapore Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 176 Singapore Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 177 Singapore Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 178 Singapore Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 179 Singapore Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 180 Singapore Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 181 Malaysia Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 182 Malaysia Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 183 Malaysia Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 184 Malaysia Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 185 Malaysia Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 186 Malaysia Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 187 Rest of Asia Pacific Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 188 Rest of Asia Pacific Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 189 Rest of Asia Pacific Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 190 Rest of Asia Pacific Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 191 Rest of Asia Pacific Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 192 Rest of Asia Pacific Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 193 LAMEA Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 194 LAMEA Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 195 LAMEA Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 196 LAMEA Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 197 LAMEA Blood Transfusion Market by Country, 2019 - 2022, USD Million
TABLE 198 LAMEA Blood Transfusion Market by Country, 2023 - 2030, USD Million
TABLE 199 LAMEA Pharmacotherapy Market by Country, 2019 - 2022, USD Million
TABLE 200 LAMEA Pharmacotherapy Market by Country, 2023 - 2030, USD Million
TABLE 201 LAMEA Bone Marrow Transplant Market by Country, 2019 - 2022, USD Million
TABLE 202 LAMEA Bone Marrow Transplant Market by Country, 2023 - 2030, USD Million
TABLE 203 LAMEA Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 204 LAMEA Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 205 LAMEA Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 206 LAMEA Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 207 LAMEA Specialty Clinics Market by Country, 2019 - 2022, USD Million
TABLE 208 LAMEA Specialty Clinics Market by Country, 2023 - 2030, USD Million
TABLE 209 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 210 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 211 LAMEA Sickle Cell Disease Treatment Market by Country, 2019 - 2022, USD Million
TABLE 212 LAMEA Sickle Cell Disease Treatment Market by Country, 2023 - 2030, USD Million
TABLE 213 Brazil Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 214 Brazil Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 215 Brazil Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 216 Brazil Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 217 Brazil Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 218 Brazil Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 219 Argentina Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 220 Argentina Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 221 Argentina Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 222 Argentina Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 223 Argentina Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 224 Argentina Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 225 UAE Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 226 UAE Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 227 UAE Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 228 UAE Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 229 UAE Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 230 UAE Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 231 Saudi Arabia Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 232 Saudi Arabia Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 233 Saudi Arabia Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 234 Saudi Arabia Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 235 Saudi Arabia Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 236 Saudi Arabia Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 237 South Africa Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 238 South Africa Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 239 South Africa Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 240 South Africa Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 241 South Africa Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 242 South Africa Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 243 Nigeria Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 244 Nigeria Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 245 Nigeria Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 246 Nigeria Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 247 Nigeria Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 248 Nigeria Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 249 Rest of LAMEA Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 250 Rest of LAMEA Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 251 Rest of LAMEA Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 252 Rest of LAMEA Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 253 Rest of LAMEA Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 254 Rest of LAMEA Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 255 Key Information - bluebird bio, Inc.
TABLE 256 Key Information - CRISPR Therapeutics AG
TABLE 257 Key Information - Agios Pharmaceuticals, Inc.
TABLE 258 Key Information - Medunik USA
TABLE 259 Key Information - CSL Limited
TABLE 260 Key Information - Novo Nordisk A/S
TABLE 261 Key Information - Novartis AG
TABLE 262 Key Information - Pfizer, Inc.
TABLE 263 Key Information - Bristol Myers Squibb Company
TABLE 264 Key Information - Emmaus Life Sciences, INC.

List of Figures

FIG 1 Methodology for the research
FIG 2 Global Sickle Cell Disease Treatment Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Sickle Cell Disease Treatment Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: Partnerships, Collaborations & Agreements: 2019, Feb - 2022, Jun) Leading Players
FIG 7 Porter's Five Forces Analysis - Sickle Cell Disease Treatment Market
FIG 8 Global Sickle Cell Disease Treatment Market share by Treatment, 2022
FIG 9 Global Sickle Cell Disease Treatment Market share by Treatment, 2030
FIG 10 Global Sickle Cell Disease Treatment Market by Treatment, 2019 - 2030, USD Million
FIG 11 Global Sickle Cell Disease Treatment Market share by End-use, 2022
FIG 12 Global Sickle Cell Disease Treatment Market share by End-use, 2030
FIG 13 Global Sickle Cell Disease Treatment Market by End-use, 2019 - 2030, USD Million
FIG 14 Global Sickle Cell Disease Treatment Market share by Region, 2022
FIG 15 Global Sickle Cell Disease Treatment Market share by Region, 2030
FIG 16 Global Sickle Cell Disease Treatment Market by Region, 2019 - 2030, USD Million
FIG 17 SWOT Analysis: bluebird bio, Inc.
FIG 18 SWOT Analysis: CRISPR Therapeutics AG
FIG 19 SWOT Analysis: Agios Pharmaceuticals, Inc.
FIG 20 SWOT Analysis: Medunik USA
FIG 21 SWOT Analysis: CSL Limited
FIG 22 SWOT Analysis: Novo Nordisk A/S
FIG 23 Recent strategies and developments: Novartis AG
FIG 24 SWOT Analysis: Novartis AG
FIG 25 SWOT Analysis: Pfizer, Inc.
FIG 26 SWOT Analysis: Bristol Myers Squibb Company
FIG 27 Recent strategies and developments: Emmaus Life Sciences, Inc.
FIG 28 SWOT Analysis: Emmaus Life Sciences, Inc.

The Global Sickle Cell Disease Treatment Market size is expected to reach $7.3 billion by 2030, rising at a market growth of 27.9% CAGR during the forecast period.

According to a study by NCBI in 2021, the disease can expose patients to up to 18 VOCs per year. The increasing prevalence of SCD and the efficacy of the products used to treat the disease in decreasing the risk of VOCs are boosting the product's usage among the patient population. Therefore, The Bone Marrow Transplant segment would capture 1/5thshare in the market by 2030, as the incidence of SCD disease has been rising more quickly. Vaso-occlusive crisis is a frequent and excruciating complication of sickle cell disease in adolescents and adults. By replacing the patient's diseased bone marrow with healthy donor marrow, this procedure can effectively eliminate the root cause of SCD, which is the production of abnormal hemoglobin. It causes episodes of acute, excruciating pain causing patients, including infants and adults, to seek urgent medical care.

The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In June, 2022, Novartis AG came into partnership with Precision BioSciences, Inc, to develop solutions for in vivo gene editing. Through the partnership, Novartis AG would be better positioned to provide effective treatment for patients with hemoglobinopathies. Additionally, In November, 2021, Emmaus Life Sciences, Inc. partnered with UpScript IP Holdings, LLC, to provide telehealth solutions for patients with sickle cell disease.

Based on the Analysis presented in the KBV Cardinal matrix; Pfizer Inc. is the forerunner in the Market. Companies such as Novo Nordisk A/S, Novartis AG, Bristol Myers Squibb Company are some of the key innovators in the Market. In October, 2019, Novo Nordisk A/S signed a partnership with bluebird bio, Inc, to develop in vivo genome editing treatments for inherited diseases. Through the partnership, Novo Nordisk would be better positioned to develop disease-modifying medicines.

COVID-19 Impact Analysis

Workflows in the healthcare industry were hampered by the COVID-19 pandemic all over the world. Several industries, including several sub-domains of healthcare, were compelled to close temporarily due to the disease outbreak. A further factor limiting market expansion was the disruption of the sickle cell disease drug supply chain during COVID-19. Additionally, the lockdown had a detrimental effect on hospital admissions, affecting the market. In the later phases of the pandemic, the growth of the blood transfusion and bone marrow transplant industries returned to normal due to a rise in population vaccination, the implementation of stringent COVID-19 guidelines, and the lifting of travel restrictions. Therefore, the pandemic had a significant negative impact on the market.

Market Growth Factors

Development of new treatment methods

Earlier, blood transfusions and bone marrow transplants were the only treatments for SCD. The increasing prevalence and awareness of the disease boosted the demand for alternative, effective treatment types. Major players have increased their emphasis on introducing new products to treat this disease to meet market demand. Endari was the first branded drug to be approved in decades, before which there was a limited emphasis on innovation in devising a treatment for the disease. Sickle cell disease patients without a suitable donor may be cured by genetic therapies that alter their own hematopoietic stem cells. Such development increases the number of available treatments for SCD and may cover a large proportion of patient base, and thus, aids in the growth of the market.

Modernization of clinical trials and pharmaceutical research

Leaders in the pharmaceutical research industry are now exploring to implement efficient ways of doing the RD processes, for which machine learning appear to be a promising solution. The top pharmaceutical companies in the world are using machine learning to better the hit-and-miss process of discovering new treatments. In addition, many large pharmaceutical companies are investigating the potential of big data to speed up the drug discovery process. This would lead to smaller, quicker, and more affordable trials overall. For greater safety, ML can also be used for remote monitoring and real-time data access. Therefore, the advancement of clinical trials and R&D in the pharma sector with ML, which enables faster and more effective drug development, will propel the market growth.

Market Restraining Factors

Minimal treatment options available for SCD

Hydroxyurea and a few branded medications are the pharmacotherapy used to treat sickle cell disease. Numerous healthcare professionals recommend hydroxyurea as the first-line treatment for the disease. However, the absence of treatment options in countries and regions around the world stands out as a significant constraining factor. Despite its inclusion on the WHO Model List of Essential Medicines for Children, hydroxyurea is still unavailable in the region. In addition, the substance is considered too costly in Africa. In addition, the lack of awareness of the disease among the population in developing economies can hinder the development of the market during the forecast period.

Treatment Outlook

By treatment, the market is categorized into blood transfusion, pharmacotherapy, and bone marrow transplant. The bone marrow transplant segment covered a considerable revenue share in the market in 2022. The segment has experienced rapid expansion due to the emergence of new, branded pharmaceutical medications and growing government incentives to launch these drugs early. The government provides funding and designations such as orphan pharmaceuticals, fast track, and priority review, among others, to support sickle cell disease research.

End-Use Outlook

Based on end-use, the market is classified into hospitals, specialty clinics, and others. In 2022 the hospitals segment witnessed the largest revenue share in the market. The primary centres for disease diagnosis and treatment are hospitals. Most blood transfusions and bone marrow transplants are performed in hospitals. In addition, superior healthcare services, a large patient pool, and an enhanced healthcare infrastructure are some of the primary reasons for the segment's large market share.

Regional Outlook

Region wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022 the North America region led the market by generating the highest revenue share. The expansion in the region can be attributed to the increased availability of SCD treatments and promising pipeline candidates. Strong government support in the United States will further promote market growth. The region's market is anticipated to grow faster than average due to the increasing incidence of sickle cell disease, the rising number of clinical trials, and the increasing number of product launches.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Novartis AG, Pfizer Inc., bluebird bio, Inc., CSL Limited, Emmaus Life Sciences, Inc., Bristol Myers Squibb Company, CRISPR Therapeutics AG, Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS), Novo Nordisk A/S and Medunik USA (Duchesnay Inc.)

Recent Strategies Deployed in Sickle Cell Disease Treatment Market

Partnerships, Collaborations & Agreements:

Jun-2022: Novartis AG came into partnership with Precision BioSciences, Inc., a biotechnology company based in the United States, to develop solutions for in vivo gene editing. Through the partnership, Novartis AG would be better positioned to provide effective treatment for patients with hemoglobinopathies.

Nov-2021: Emmaus Life Sciences, Inc. partnered with UpScript IP Holdings, LLC, a pharmaceutical company, to provide telehealth solutions for patients with sickle cell disease. The partnership would allow Emmaus Life Sciences to provide patients with access to its Endari treatment.

Jul-2021: Bluebird Bio, Inc. signed a partnership with National Resilience, Inc., a biotechnology company, to develop solutions for cell therapies. The partnership comes in line with Bluebird's ambition for the development of effective cell therapies.

Apr-2021: CRISPR Therapeutics AG entered into a partnership with Vertex Pharmaceuticals Incorporated, a US-based biotechnology company, to market its CTX001 gene editing therapy for sickle cell disease treatment. The partnership would extend the global reach of CRISPR's CTX001 gene editing therapy.

Feb-2021: Novartis AG announced a partnership with Bill & Melinda Gates Foundation, an American private foundation, to develop solutions for vivo gene therapy for sickle cell disease treatment. The partnership would pave the way for effective sickle cell disease treatment for patients around the world.

Mergers & Acquisition:

Oct-2022: Pfizer Inc. acquired Global Blood Therapeutics, Inc., a biopharmaceutical company. The acquisition strengthens Pfizer's capabilities to provide sickle cell disease treatment solutions.

Sep-2022: Novo Nordisk A/S announced the acquisition of Forma Therapeutics, a biotech company specializing in sickle cell disease (SCD) treatment. The acquisition enhances Novo Nordisk's sickle cell disease treatment offerings.

Product Launches and Product Expansions:

Apr-2022: Emmaus Life Sciences, Inc. announced the launch of a full-service telehealth solution. The solutions feature improved access to Endari sickle disease treatment drugs. The launch extends Endari's reach to a wider population of patients with sickle cell disease.

Trials and Approvals:

Jul-2023: The Oman Ministry of Health approved Emmaus Life Sciences' Endari, an Oral medicine used for the treatment of sickle cell disease.

Dec-2021: Medunik USA received approval from The Food and Drug Administration (FDA) for new applications of its Siklos, a sickle cell anemia treatment solution.

Nov-2020: Agios Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its mitapivat, a pyruvate kinase R (PKR) activator used for the treatment of sickle cell disease.

Oct-2020: Novartis AG received approval from the European Commission (EC) for its Adakveo, a sickle cell disease treatment used for the prevention of recurrent vaso-occlusive crises (VOCs).

Scope of the Study

Market Segments covered in the Report:

By Treatment

Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant

By End-Use

Hospitals
Specialty Clinics
Others

By Geography

North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA

Companies Profiled

Novartis AG
Pfizer Inc.
bluebird bio, Inc.
CSL Limited
Emmaus Life Sciences, Inc.
Bristol Myers Squibb Company
CRISPR Therapeutics AG
Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS)
Novo Nordisk A/S
Medunik USA (Duchesnay Inc.)

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Global Sickle Cell Disease Treatment Market, by Treatment
- 1.4.2 Global Sickle Cell Disease Treatment Market, by End-Use
- 1.4.3 Global Sickle Cell Disease Treatment Market, by Geography
1.5 Methodology for the research

Chapter 2. Market at a Glance

2.1 Key Highlights

Chapter 3. Market Overview

3.1 Introduction
- 3.1.1 Overview
  - 3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints

Chapter 4. Competition Analysis - Global

4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
- 4.2.1 Partnerships, Collaborations and Agreements
- 4.2.2 Product Launches and Product Expansions
- 4.2.3 Acquisition and Mergers
- 4.2.4 Trials and Approvals
4.3 Top Winning Strategies
- 4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
- 4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, Feb - 2022, Jun) Leading Players
4.4 Porter Five Forces Analysis

Chapter 5. Global Sickle Cell Disease Treatment Market by Treatment

5.1 Global Blood Transfusion Market by Region
5.2 Global Pharmacotherapy Market by Region
5.3 Global Bone Marrow Transplant Market by Region

Chapter 6. Global Sickle Cell Disease Treatment Market by End-use

6.1 Global Hospitals Market by Region
6.2 Global Specialty Clinics Market by Region
6.3 Global Others Market by Region

Chapter 7. Global Sickle Cell Disease Treatment Market by Region

7.1 North America Sickle Cell Disease Treatment Market
- 7.1.1 North America Sickle Cell Disease Treatment Market by Treatment
  - 7.1.1.1 North America Blood Transfusion Market by Country
  - 7.1.1.2 North America Pharmacotherapy Market by Country
  - 7.1.1.3 North America Bone Marrow Transplant Market by Country
- 7.1.2 North America Sickle Cell Disease Treatment Market by End-use
  - 7.1.2.1 North America Hospitals Market by Country
  - 7.1.2.2 North America Specialty Clinics Market by Country
  - 7.1.2.3 North America Others Market by Country
- 7.1.3 North America Sickle Cell Disease Treatment Market by Country
  - 7.1.3.1 US Sickle Cell Disease Treatment Market
    - 7.1.3.1.1 US Sickle Cell Disease Treatment Market by Treatment
    - 7.1.3.1.2 US Sickle Cell Disease Treatment Market by End-use
  - 7.1.3.2 Canada Sickle Cell Disease Treatment Market
    - 7.1.3.2.1 Canada Sickle Cell Disease Treatment Market by Treatment
    - 7.1.3.2.2 Canada Sickle Cell Disease Treatment Market by End-use
  - 7.1.3.3 Mexico Sickle Cell Disease Treatment Market
    - 7.1.3.3.1 Mexico Sickle Cell Disease Treatment Market by Treatment
    - 7.1.3.3.2 Mexico Sickle Cell Disease Treatment Market by End-use
  - 7.1.3.4 Rest of North America Sickle Cell Disease Treatment Market
    - 7.1.3.4.1 Rest of North America Sickle Cell Disease Treatment Market by Treatment
    - 7.1.3.4.2 Rest of North America Sickle Cell Disease Treatment Market by End-use
7.2 Europe Sickle Cell Disease Treatment Market
- 7.2.1 Europe Sickle Cell Disease Treatment Market by Treatment
  - 7.2.1.1 Europe Blood Transfusion Market by Country
  - 7.2.1.2 Europe Pharmacotherapy Market by Country
  - 7.2.1.3 Europe Bone Marrow Transplant Market by Country
- 7.2.2 Europe Sickle Cell Disease Treatment Market by End-use
  - 7.2.2.1 Europe Hospitals Market by Country
  - 7.2.2.2 Europe Specialty Clinics Market by Country
  - 7.2.2.3 Europe Others Market by Country
- 7.2.3 Europe Sickle Cell Disease Treatment Market by Country
  - 7.2.3.1 Germany Sickle Cell Disease Treatment Market
    - 7.2.3.1.1 Germany Sickle Cell Disease Treatment Market by Treatment
    - 7.2.3.1.2 Germany Sickle Cell Disease Treatment Market by End-use
  - 7.2.3.2 UK Sickle Cell Disease Treatment Market
    - 7.2.3.2.1 UK Sickle Cell Disease Treatment Market by Treatment
    - 7.2.3.2.2 UK Sickle Cell Disease Treatment Market by End-use
  - 7.2.3.3 France Sickle Cell Disease Treatment Market
    - 7.2.3.3.1 France Sickle Cell Disease Treatment Market by Treatment
    - 7.2.3.3.2 France Sickle Cell Disease Treatment Market by End-use
  - 7.2.3.4 Russia Sickle Cell Disease Treatment Market
    - 7.2.3.4.1 Russia Sickle Cell Disease Treatment Market by Treatment
    - 7.2.3.4.2 Russia Sickle Cell Disease Treatment Market by End-use
  - 7.2.3.5 Spain Sickle Cell Disease Treatment Market
    - 7.2.3.5.1 Spain Sickle Cell Disease Treatment Market by Treatment
    - 7.2.3.5.2 Spain Sickle Cell Disease Treatment Market by End-use
  - 7.2.3.6 Italy Sickle Cell Disease Treatment Market
    - 7.2.3.6.1 Italy Sickle Cell Disease Treatment Market by Treatment
    - 7.2.3.6.2 Italy Sickle Cell Disease Treatment Market by End-use
  - 7.2.3.7 Rest of Europe Sickle Cell Disease Treatment Market
    - 7.2.3.7.1 Rest of Europe Sickle Cell Disease Treatment Market by Treatment
    - 7.2.3.7.2 Rest of Europe Sickle Cell Disease Treatment Market by End-use
7.3 Asia Pacific Sickle Cell Disease Treatment Market
- 7.3.1 Asia Pacific Sickle Cell Disease Treatment Market by Treatment
  - 7.3.1.1 Asia Pacific Blood Transfusion Market by Country
  - 7.3.1.2 Asia Pacific Pharmacotherapy Market by Country
  - 7.3.1.3 Asia Pacific Bone Marrow Transplant Market by Country
- 7.3.2 Asia Pacific Sickle Cell Disease Treatment Market by End-use
  - 7.3.2.1 Asia Pacific Hospitals Market by Country
  - 7.3.2.2 Asia Pacific Specialty Clinics Market by Country
  - 7.3.2.3 Asia Pacific Others Market by Country
- 7.3.3 Asia Pacific Sickle Cell Disease Treatment Market by Country
  - 7.3.3.1 China Sickle Cell Disease Treatment Market
    - 7.3.3.1.1 China Sickle Cell Disease Treatment Market by Treatment
    - 7.3.3.1.2 China Sickle Cell Disease Treatment Market by End-use
  - 7.3.3.2 Japan Sickle Cell Disease Treatment Market
    - 7.3.3.2.1 Japan Sickle Cell Disease Treatment Market by Treatment
    - 7.3.3.2.2 Japan Sickle Cell Disease Treatment Market by End-use
  - 7.3.3.3 India Sickle Cell Disease Treatment Market
    - 7.3.3.3.1 India Sickle Cell Disease Treatment Market by Treatment
    - 7.3.3.3.2 India Sickle Cell Disease Treatment Market by End-use
  - 7.3.3.4 South Korea Sickle Cell Disease Treatment Market
    - 7.3.3.4.1 South Korea Sickle Cell Disease Treatment Market by Treatment
    - 7.3.3.4.2 South Korea Sickle Cell Disease Treatment Market by End-use
  - 7.3.3.5 Singapore Sickle Cell Disease Treatment Market
    - 7.3.3.5.1 Singapore Sickle Cell Disease Treatment Market by Treatment
    - 7.3.3.5.2 Singapore Sickle Cell Disease Treatment Market by End-use
  - 7.3.3.6 Malaysia Sickle Cell Disease Treatment Market
    - 7.3.3.6.1 Malaysia Sickle Cell Disease Treatment Market by Treatment
    - 7.3.3.6.2 Malaysia Sickle Cell Disease Treatment Market by End-use
  - 7.3.3.7 Rest of Asia Pacific Sickle Cell Disease Treatment Market
    - 7.3.3.7.1 Rest of Asia Pacific Sickle Cell Disease Treatment Market by Treatment
    - 7.3.3.7.2 Rest of Asia Pacific Sickle Cell Disease Treatment Market by End-use
7.4 LAMEA Sickle Cell Disease Treatment Market
- 7.4.1 LAMEA Sickle Cell Disease Treatment Market by Treatment
  - 7.4.1.1 LAMEA Blood Transfusion Market by Country
  - 7.4.1.2 LAMEA Pharmacotherapy Market by Country
  - 7.4.1.3 LAMEA Bone Marrow Transplant Market by Country
- 7.4.2 LAMEA Sickle Cell Disease Treatment Market by End-use
  - 7.4.2.1 LAMEA Hospitals Market by Country
  - 7.4.2.2 LAMEA Specialty Clinics Market by Country
  - 7.4.2.3 LAMEA Others Market by Country
- 7.4.3 LAMEA Sickle Cell Disease Treatment Market by Country
  - 7.4.3.1 Brazil Sickle Cell Disease Treatment Market
    - 7.4.3.1.1 Brazil Sickle Cell Disease Treatment Market by Treatment
    - 7.4.3.1.2 Brazil Sickle Cell Disease Treatment Market by End-use
  - 7.4.3.2 Argentina Sickle Cell Disease Treatment Market
    - 7.4.3.2.1 Argentina Sickle Cell Disease Treatment Market by Treatment
    - 7.4.3.2.2 Argentina Sickle Cell Disease Treatment Market by End-use
  - 7.4.3.3 UAE Sickle Cell Disease Treatment Market
    - 7.4.3.3.1 UAE Sickle Cell Disease Treatment Market by Treatment
    - 7.4.3.3.2 UAE Sickle Cell Disease Treatment Market by End-use
  - 7.4.3.4 Saudi Arabia Sickle Cell Disease Treatment Market
    - 7.4.3.4.1 Saudi Arabia Sickle Cell Disease Treatment Market by Treatment
    - 7.4.3.4.2 Saudi Arabia Sickle Cell Disease Treatment Market by End-use
  - 7.4.3.5 South Africa Sickle Cell Disease Treatment Market
    - 7.4.3.5.1 South Africa Sickle Cell Disease Treatment Market by Treatment
    - 7.4.3.5.2 South Africa Sickle Cell Disease Treatment Market by End-use
  - 7.4.3.6 Nigeria Sickle Cell Disease Treatment Market
    - 7.4.3.6.1 Nigeria Sickle Cell Disease Treatment Market by Treatment
    - 7.4.3.6.2 Nigeria Sickle Cell Disease Treatment Market by End-use
  - 7.4.3.7 Rest of LAMEA Sickle Cell Disease Treatment Market
    - 7.4.3.7.1 Rest of LAMEA Sickle Cell Disease Treatment Market by Treatment
    - 7.4.3.7.2 Rest of LAMEA Sickle Cell Disease Treatment Market by End-use

Chapter 8. Company Profiles

8.1 bluebird bio, Inc.
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Research & Development Expenses
- 8.1.4 Recent strategies and developments:
  - 8.1.4.1 Partnerships, Collaborations, and Agreements:
- 8.1.5 SWOT Analysis
8.2 CRISPR Therapeutics AG
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Research & Development Expenses
- 8.2.4 Recent strategies and developments:
  - 8.2.4.1 Partnerships, Collaborations, and Agreements:
- 8.2.5 SWOT Analysis
8.3 Agios Pharmaceuticals, Inc. (Les Laboratoires Servier SAS)
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Research & Development Expenses
- 8.3.4 Recent strategies and developments:
  - 8.3.4.1 Trials and Approvals:
- 8.3.5 SWOT Analysis
8.4 Medunik USA (Duchesnay Inc.)
- 8.4.1 Company Overview
- 8.4.2 Recent strategies and developments:
  - 8.4.2.1 Trials and Approvals:
- 8.4.3 SWOT Analysis
8.5 CSL Limited
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Segmental and Regional Analysis
- 8.5.4 Research & Development Expense
- 8.5.5 SWOT Analysis
8.6 Novo Nordisk A/S
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Segmental & Regional Analysis
- 8.6.4 Research & Development Expenses
- 8.6.5 Recent strategies and developments:
  - 8.6.5.1 Partnerships, Collaborations, and Agreements:
  - 8.6.5.2 Acquisition and Mergers:
- 8.6.6 SWOT Analysis
8.7 Novartis AG
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Segmental and Regional Analysis
- 8.7.4 Research & Development Expense
- 8.7.5 Recent strategies and developments:
  - 8.7.5.1 Partnerships, Collaborations, and Agreements:
  - 8.7.5.2 Trials and Approvals:
- 8.7.6 SWOT Analysis
8.8 Pfizer, Inc.
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Regional & Segmental Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 Recent strategies and developments:
  - 8.8.5.1 Acquisition and Mergers:
- 8.8.6 SWOT Analysis
8.9 Bristol Myers Squibb Company
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Regional Analysis
- 8.9.4 Research & Development Expenses
- 8.9.5 SWOT Analysis
8.10. Emmaus Life Sciences, Inc.
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Research & Development Expenses
- 8.10.4 Recent strategies and developments:
  - 8.10.4.1 Partnerships, Collaborations, and Agreements:
  - 8.10.4.2 Product Launches and Product Expansions:
  - 8.10.4.3 Trials and Approvals:
- 8.10.5 SWOT Analysis

鎌状赤血球症治療の世界市場規模、シェア、産業動向分析レポート：治療別、エンドユース別、地域別展望と予測、2023年～2030年

Global Sickle Cell Disease Treatment Market Size, Share & Industry Trends Analysis Report By Treatment, By End-Use, By Regional Outlook and Forecast, 2023 - 2030

目次

第1章市場範囲と調査手法

第2章市場の概要

第3章市場概要

第4章競合分析- 世界

第5章世界の鎌状赤血球症治療市場：治療別

第6章世界の鎌状赤血球症治療市場：最終用途別

第7章世界の鎌状赤血球症治療市場：地域別

第8章企業プロファイル

第9章鎌状赤血球症治療市場の勝利の必須条件

LIST OF TABLES

Scope of the Study

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market at a Glance

Chapter 3. Market Overview

Chapter 4. Competition Analysis - Global

Chapter 5. Global Sickle Cell Disease Treatment Market by Treatment

Chapter 6. Global Sickle Cell Disease Treatment Market by End-use

Chapter 7. Global Sickle Cell Disease Treatment Market by Region

Chapter 8. Company Profiles

Chapter 9. Winning Imperatives for Sickle Cell Disease Treatment Market

鎌状赤血球症治療の世界市場規模、シェア、産業動向分析レポート：治療別、エンドユース別、地域別展望と予測、2023年～2030年

Global Sickle Cell Disease Treatment Market Size, Share & Industry Trends Analysis Report By Treatment, By End-Use, By Regional Outlook and Forecast, 2023 - 2030

目次

第1章 市場範囲と調査手法

第2章 市場の概要

第3章 市場概要

第4章 競合分析- 世界

第5章 世界の鎌状赤血球症治療市場：治療別

第6章 世界の鎌状赤血球症治療市場：最終用途別

第7章 世界の鎌状赤血球症治療市場：地域別

第8章 企業プロファイル

第9章 鎌状赤血球症治療市場の勝利の必須条件

LIST OF TABLES

Scope of the Study

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market at a Glance

Chapter 3. Market Overview

Chapter 4. Competition Analysis - Global

Chapter 5. Global Sickle Cell Disease Treatment Market by Treatment

Chapter 6. Global Sickle Cell Disease Treatment Market by End-use

Chapter 7. Global Sickle Cell Disease Treatment Market by Region

Chapter 8. Company Profiles

Chapter 9. Winning Imperatives for Sickle Cell Disease Treatment Market

第1章市場範囲と調査手法

第2章市場の概要

第3章市場概要

第4章競合分析- 世界

第5章世界の鎌状赤血球症治療市場：治療別

第6章世界の鎌状赤血球症治療市場：最終用途別

第7章世界の鎌状赤血球症治療市場：地域別

第8章企業プロファイル

第9章鎌状赤血球症治療市場の勝利の必須条件